Vitalis

The US company has closed an upsized, oversubscribed Series B to advance its optogenetic gene therapy pipeline for blinding retinal diseases with Novo Holdings reinforcing a strong Nordic investment footprint in late‑stage ophthalmology.

Saphnelo (anifrolumab) has been approved in the US for self-administration as a once-weekly autoinjector, the Saphnelo Pen, for the treatment of adult patients with systemic lupus erythematosus (SLE) on top of standard therapy.

Serendo Therapeutics (SerendoTx) has been named the winner of the AbbVie Scandinavia Golden Ticket 2026, awarded in collaboration with Karolinska Institutet Innovation.

AddLife has acquired CoaChrom Diagnostica, an Austrian niche company specializing in advanced coagulation diagnostics.

For a long time, restoring vision has been like a search for the holy grail for scientists. And for many patients, being diagnosed with a severe retinal disease has meant progressive, irreversible vision loss. However, the past decade has seen some  of the clearest evidence so far that vision loss can be partially restored, not just preserved.

Sweden’s first clinical research center dedicated to ophthalmology has been established at St. Erik Eye Hospital in the Stockholm Region, in collaboration with Karolinska Institutet.

Following Diamyd Medical’s negative results from the March 27 interim analysis of its DIAGNODE-3 study, the Board of Directors has implemented governance changes to strengthen oversight and strategic direction.